Treatment of cancer
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|Treatment of cancer|
Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality, most commonly as a series of separate treatments (e.g. chemotherapy before surgery). The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of the patient (performance status). Cancer genome sequencing helps in determining which cancer the patient exactly has for determining the best therapy for the cancer. A number of experimental cancer treatments are also under development. Under current estimates, two in five people will have cancer at some point in their lifetime.
Complete removal of the cancer without damage to the rest of the body (that is, achieving cure with near-zero adverse effects) is the ideal, if rarely achieved, goal of treatment and is often the goal in practice. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness; and chemotherapy and radiotherapy can have a negative effect on normal cells. Therefore, cure with nonnegligible adverse effects may be accepted as a practical goal in some cases; and besides curative intent, practical goals of therapy can also include (1) suppressing the cancer to a subclinical state and maintaining that state for years of good quality of life (that is, treating the cancer as a chronic disease), and (2) palliative care without curative intent (for advanced-stage metastatic cancers).
Because "cancer" refers to a class of diseases, it is unlikely that there will ever be a single "cure for cancer" any more than there will be a single treatment for all infectious diseases. Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but this has not been the case in practice.
Types of treatments
The treatment of cancer has undergone evolutionary changes as understanding of the underlying biological processes has increased. Tumor removal surgeries have been documented in ancient Egypt, hormone therapy and radiation therapy were developed in the late 19th century. Chemotherapy, immunotherapy and newer targeted therapies are products of the 20th century. As new information about the biology of cancer emerges, treatments will be developed and modified to increase effectiveness, precision, survivability, and quality of life.
In theory, non-hematological cancers can be cured if entirely removed by surgery, but this is not always possible. When the cancer has metastasized to other sites in the body prior to surgery, complete surgical excision is usually impossible. In the Halstedian model of cancer progression, tumors grow locally, then spread to the lymph nodes, then to the rest of the body. This has given rise to the popularity of local-only treatments such as surgery for small cancers. Even small localized tumors are increasingly recognized as possessing metastatic potential.
Examples of surgical procedures for cancer include mastectomy for breast cancer, prostatectomy for prostate cancer, and lung cancer surgery for non-small cell lung cancer. The goal of the surgery can be either the removal of only the tumor, or the entire organ. A single cancer cell is invisible to the naked eye but can regrow into a new tumor, a process called recurrence. For this reason, the pathologist will examine the surgical specimen to determine if a margin of healthy tissue is present, thus decreasing the chance that microscopic cancer cells are left in the patient.
In addition to removal of the primary tumor, surgery is often necessary for staging, e.g. determining the extent of the disease and whether it has metastasized to regional lymph nodes. Staging is a major determinant of prognosis and of the need for adjuvant therapy. Occasionally, surgery is necessary to control symptoms, such as spinal cord compression or bowel obstruction. This is referred to as palliative treatment.
Surgery may be performed before or after other forms of treatment. Treatment before surgery is often described as neoadjuvant. In breast cancer, the survival rate of patients who receive neoadjuvant chemotherapy are no different to those who are treated following surgery. Giving chemotherapy earlier allows oncologists to evaluate the effectiveness of the therapy, and may make removal of the tumor easier. However, the survival advantages of neoadjuvant treatment in lung cancer are less clear.
Radiation therapy (also called radiotherapy, X-ray therapy, or irradiation) is the use of ionizing radiation to kill cancer cells and shrink tumors. Radiation therapy can be administered externally via external beam radiotherapy (EBRT) or internally via brachytherapy. The effects of radiation therapy are localised and confined to the region being treated. Radiation therapy injures or destroys cells in the area being treated (the "target tissue") by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue. Hence, it is given in many fractions, allowing healthy tissue to recover between fractions.
Radiation therapy may be used to treat almost every type of solid tumor, including cancers of the brain, breast, cervix, larynx, liver, lung, pancreas, prostate, skin, stomach, uterus, or soft tissue sarcomas. Radiation is also used to treat leukemia and lymphoma. Radiation dose to each site depends on a number of factors, including the radio sensitivity of each cancer type and whether there are tissues and organs nearby that may be damaged by radiation. Thus, as with every form of treatment, radiation therapy is not without its side effects.
Radiation therapy kills cancer cells by damaging their DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next) (1).Radiation therapy can either damage DNA directly or create charged particles (free radicals) within the cells that can in turn damage the DNA. (2) Radiation therapy can lead to dry mouth from exposure of salivary glands to radiation. The salivary glands lubricate the mouth with moisture or spit. Post therapy, the salivary glands will resume functioning but rarely in the same fashion. Dry mouth caused by radiation can be a lifelong problem. The specifics of your brain cancer radiation therapy plan will be based on several factors, including the type and size of the brain tumor and the extent of disease. External beam radiation is commonly used for brain cancer. The area radiated typically includes the tumor and an area surrounding the tumor. For metastatic brain tumors, radiation is sometimes given to the entire brain. Radiation therapy uses special equipment to send high doses of radiation to the cancer cells. Most cells in the body grow and divide to form new cells. But cancer cells grow and divide faster than many of the normal cells around them. Radiation works by making small breaks in the DNA inside cell.
Radiation might not be a choice of treatment if the tumour was diagnosed on the late stage or is located on vulnerable places. Moreover, radiation causes significant side effects if used in children aged 0–14. It was determined to be a beneficial treatment but it causes significant side effects that influence the lifestyle of the young patients. Radiotherapy is the use of high-energy rays, usually x-rays and similar rays (such as electrons) to treat disease. It works by destroying cancer cells in the area that's treated. Although normal cells can also be damaged by radiotherapy, they can usually repair themselves, but cancer cells can't. If the tumour was found on the late stage, it requires patients to have higher radiation exposure which might be harmful for the organs. Radiotherapy is determined to be an effective treatment in adults but it causes significant side effects that can influence patients` daily living. In children radiotherapy mostly causes long-term side effects such as hearing loss and blindness. Children who had received cranial radiotherapy are deemed at a high risk for academic failure and cognitive delay.
A study by Reddy A.T. determined the significant decrease in IQ with higher doses of radiation, specifically for children with brain tumours. Radiation therapy is not the best treatment for brain tumours, especially in young children as it causes significant damages. There are alternative treatments available for young patients such as surgical resection to decrease the occurrence of side effects.
Chemotherapy is the treatment of cancer with drugs ("anticancer drugs") that can destroy cancer cells. In current usage, the term "chemotherapy" usually refers to cytotoxic drugs which affect rapidly dividing cells in general, in contrast with targeted therapy (see below). Chemotherapy drugs interfere with cell division in various possible ways, e.g. with the duplication of DNA or the separation of newly formed chromosomes. Most forms of chemotherapy target all rapidly dividing cells and are not specific to cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair DNA damage, while normal cells generally can. Hence, chemotherapy has the potential to harm healthy tissue, especially those tissues that have a high replacement rate (e.g. intestinal lining). These cells usually repair themselves after chemotherapy.
Because some drugs work better together than alone, two or more drugs are often given at the same time. This is called "combination chemotherapy"; most chemotherapy regimens are given in a combination.
The treatment of some leukaemias and lymphomas requires the use of high-dose chemotherapy, and total body irradiation (TBI). This treatment ablates the bone marrow, and hence the body's ability to recover and repopulate the blood. For this reason, bone marrow, or peripheral blood stem cell harvesting is carried out before the ablative part of the therapy, to enable "rescue" after the treatment has been given. This is known as autologous stem cell transplantation.
Targeted therapy, which first became available in the late 1990s, has had a significant impact in the treatment of some types of cancer, and is currently a very active research area. This constitutes the use of agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs are generally inhibitors of enzymatic domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors imatinib (Gleevec/Glivec) and gefitinib (Iressa).
Monoclonal antibody therapy is another strategy in which the therapeutic agent is an antibody which specifically binds to a protein on the surface of the cancer cells. Examples include the anti-HER2/neu antibody trastuzumab (Herceptin) used in breast cancer, and the anti-CD20 antibody rituximab, used in a variety of B-cell malignancies.
Targeted therapy can also involve small peptides as "homing devices" which can bind to cell surface receptors or affected extracellular matrix surrounding the tumor. Radionuclides which are attached to these peptides (e.g. RGDs) eventually kill the cancer cell if the nuclide decays in the vicinity of the cell. Especially oligo- or multimers of these binding motifs are of great interest, since this can lead to enhanced tumor specificity and avidity.
Photodynamic therapy (PDT) is a ternary treatment for cancer involving a photosensitizer, tissue oxygen, and light (often using lasers). PDT can be used as treatment for basal cell carcinoma (BCC) or lung cancer; PDT can also be useful in removing traces of malignant tissue after surgical removal of large tumors. In February 2019, medical scientists announced that iridium attached to albumin, creating a photosensitized molecule, can penetrate cancer cells and, after being irradiated with light, destroy the cancer cells.
High-energy therapeutic ultrasound could increase higher-density anti-cancer drug load and nanomedicines to target tumor sites by 20x fold higher than traditional target cancer therapy.
Targeted therapies under pre-clinical development as potential cancer treatments include morpholino splice switching oligonucleotides, which induce ERG exon skipping in prostate cancer models, multitargeted kinase inhibitors that inhibit the PI3K with other pathways including MEK and PIM, and inhibitors of NFKB in models of chemotherapy resistance.
Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own immune system to fight the tumor. Contemporary methods for generating an immune response against tumours include intravesical BCG immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to induce an immune response in renal cell carcinoma and melanoma patients. Cancer vaccines to generate specific immune responses are the subject of intensive research for a number of tumours, notably malignant melanoma and renal cell carcinoma. Sipuleucel-T is a vaccine-like strategy in late clinical trials for prostate cancer in which dendritic cells from the patient are loaded with prostatic acid phosphatase peptides to induce a specific immune response against prostate-derived cells.
Allogeneic hematopoietic stem cell transplantation ("bone marrow transplantation" from a genetically non-identical donor) can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a phenomenon known as graft-versus-tumor effect. For this reason, allogeneic HSCT leads to a higher cure rate than autologous transplantation for several cancer types, although the side effects are also more severe.
The cell based immunotherapy in which the patients own Natural Killer cells(NK) and Cytotoxic T-Lymphocytes(CTL) are used has been in practice in Japan since 1990. NK cells and CTLs primarily kill the cancer cells when they are developed. This treatment is given together with the other modes of treatment such as surgery, radiotherapy or chemotherapy and called as Autologous Immune Enhancement Therapy (AIET).
Immune Checkpoint therapy focuses on two "checkpoint" proteins, cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Under normal conditions, the immune system utilizes checkpoint proteins as negative feedback mechanisms to return to homeostasis once pathogens have been cleared from the body. In tumor microenvironment, cancer cells can commandeer this physiological regulatory system to "put a brake" on the anti-cancer immune response and evade immune surveillance. 2018 Nobel Prize in medicine is awarded to Dr. James Allison of University of Texas MD Anderson Cancer Center in U.S. and Dr. Tasuku Honjo Kyoto University in Japan for their contributions in advance of PD-1 and CTLA-4 immune checkpoint therapy.
The growth of some cancers can be inhibited by providing or blocking certain hormones. Common examples of hormone-sensitive tumors include certain types of breast and prostate cancers. Blocking estrogen or testosterone is often an important additional treatment. In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial.
Angiogenesis inhibitors prevent the extensive growth of blood vessels (angiogenesis) that tumors require to survive. Some, such as bevacizumab, have been approved and are in clinical use. One of the main problems with anti-angiogenesis drugs is that many factors stimulate blood vessel growth in cells normal or cancerous. Anti-angiogenesis drugs only target one factor, so the other factors continue to stimulate blood vessel growth. Other problems include route of administration, maintenance of stability and activity and targeting at the tumor vasculature.
Synthetic lethality arises when a combination of deficiencies in the expression of two or more genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of one or both of the genes.
Cancer cells are frequently deficient in a DNA repair gene. (Also see DNA repair deficiency in cancer.) This DNA repair defect either may be due to mutation or, often, epigenetic silencing (see epigenetic silencing of DNA repair). If this DNA repair defect is in one of seven DNA repair pathways (see DNA repair pathways), and a compensating DNA repair pathway is inhibited, then the tumor cells may be killed by synthetic lethality. Non-tumorous cells, with the initial pathway intact, can survive.
Mutations in DNA repair genes BRCA1 or BRCA2 (active in homologous recombinational repair) are synthetically lethal with inhibition of DNA repair gene PARP1 (active in the base excision repair and in the microhomology-mediated end joining pathways of DNA repair).
Ovarian cancers have a mutational defect in BRCA1 in about 18% of patients (13% germline mutations and 5% somatic mutations) (see BRCA1). Olaparib, a PARP inhibitor, was approved in 2014 by the US FDA for use in BRCA-associated ovarian cancer that had previously been treated with chemotherapy. The FDA, in 2016, also approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation.
In colon cancer, epigenetic defects in the WRN gene appear to be synthetically lethal with inactivation of TOP1. In particular, irinotecan inactivation of TOP1 was synthetically lethal with deficient expression of the DNA repair WRN gene in patients with colon cancer. In a 2006 study, 45 patients had colonic tumors with hypermethylated WRN gene promoters (silenced WRN expression), and 43 patients had tumors with unmethylated WRN gene promoters, so that WRN protein expression was high. Irinotecan was more strongly beneficial for patients with hypermethylated WRN promoters (39.4 months survival) than for those with unmethylated WRN promoters (20.7 months survival). The WRN gene promoter is hypermethylated in about 38% of colorectal cancers.
There are five different stages of colon cancer, and these five stages all have treatment:
- Stage 0, is where the patient is required to undergo surgery to remove the polyp (American Cancer Society).
- Stage 1, depending on the location of the cancer in the colon and lymph nodes, the patient undergoes surgery just like Stage 0.
- Stage 2 patients undergoes removing nearby lymph nodes, but depending on what the doctor says, the patent might have to undergo chemotherapy after surgery (if the cancer is at higher risk of coming back).
- Stage 3, is where the cancer has spread all throughout the lymph nodes but not yet to other organs or body parts. When getting to this stage, Surgery is conducted on the colon and lymph nodes, then the doctor orders Chemotherapy (FOLFOX or CapeOx) to treat the colon cancer in the location needed (American Cancer Society). The last a patient can get is Stage 4.
- Stage 4 patients only undergo surgery if it is for the prevention of the cancer, along with pain relief. If the pain continues with these two options, the doctor might recommended radiation therapy. The main treatment strategy is chemotherapy due to how aggressive the cancer becomes in this stage, not only to the colon but to the lymph nodes.
Cancer pain management
Symptom control and palliative care
Although the control of the symptoms of cancer is not typically thought of as a treatment directed at the cancer, it is an important determinant of the quality of life of cancer patients, and plays an important role in the decision whether the patient is able to undergo other treatments. Although doctors generally have the therapeutic skills to reduce pain, chemotherapy-induced nausea and vomiting, diarrhea, hemorrhage and other common problems in cancer patients, the multidisciplinary specialty of palliative care has arisen specifically in response to the symptom control needs of this group of patients.
Pain medication, such as morphine and oxycodone, and antiemetics, drugs to suppress nausea and vomiting, are very commonly used in patients with cancer-related symptoms. Improved antiemetics such as ondansetron and analogues, as well as aprepitant have made aggressive treatments much more feasible in cancer patients.
Cancer pain can be associated with continuing tissue damage due to the disease process or the treatment (i.e. surgery, radiation, chemotherapy). Although there is always a role for environmental factors and affective disturbances in the genesis of pain behaviors, these are not usually the predominant etiologic factors in patients with cancer pain. Some patients with severe pain associated with cancer are nearing the end of their lives, but in all cases palliative therapies should be used to control the pain. Issues such as social stigma of using opioids, work and functional status, and health care consumption can be concerns and may need to be addressed in order for the person to feel comfortable taking the medications required to control his or her symptoms. The typical strategy for cancer pain management is to get the patient as comfortable as possible using the least amount of medications possible but opioids, surgery, and physical measures are often required.
Historically, doctors were reluctant to prescribe narcotics to terminal cancer patients due to addiction and respiratory function suppression. The palliative care movement, a more recent offshoot of the hospice movement, has engendered more widespread support for preemptive pain treatment for cancer patients. The World Health Organization also noted uncontrolled cancer pain as a worldwide problem and established a "ladder" as a guideline for how practitioners should treat pain in patients who have cancer 
Cancer-related fatigue is a very common problem for cancer patients, and has only recently become important enough for oncologists to suggest treatment, even though it plays a significant role in many patients' quality of life.
Hospice in cancer
Hospice is a group that provides care at the home of a person that has an advanced illness with a likely prognosis of less than 6 months. As most treatments for cancer involve significant unpleasant side effects, a patient with little realistic hope of a cure or prolonged life may choose to seek comfort care only, forgoing more radical therapies in exchange for a prolonged period of normal living. This is an especially important aspect of care for those patients whose disease is not a good candidate for other forms of treatment. In these patients, the risks related to the chemotherapy may actually be higher than the chance of responding to the treatment, making further attempts to cure the disease impossible. Of note, patients on hospice can sometimes still get treatments such as radiation therapy if it is being used to treat symptoms, not as an attempt to cure the cancer.
Clinical trials, also called research studies, test new treatments in people with cancer. The goal of this research is to find better ways to treat cancer and help cancer patients. Clinical trials test many types of treatment such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as gene therapy.
A clinical trial is one of the final stages of a long and careful cancer research process. The search for new treatments begins in the laboratory, where scientists first develop and test new ideas. If an approach seems promising, the next step may be testing a treatment in animals to see how it affects cancer in a living being and whether it has harmful effects. Of course, treatments that work well in the lab or in animals do not always work well in people. Studies are done with cancer patients to find out whether promising treatments are safe and effective.
Patients who take part may be helped personally by the treatment they receive. They get up-to-date care from cancer experts, and they receive either a new treatment being tested or the best available standard treatment for their cancer. At the same time, new treatments also may have unknown risks, but if a new treatment proves effective or more effective than standard treatment, study patients who receive it may be among the first to benefit. There is no guarantee that a new treatment being tested or a standard treatment will produce good results. In children with cancer, a survey of trials found that those enrolled in trials were on average not more likely to do better or worse than those on standard treatment; this confirms that success or failure of an experimental treatment cannot be predicted.
Exosomes are lipid-covered microvesicles shed by solid tumors into bodily fluids, such as blood and urine. Current research is being done attempting to use exosomes as a detection and monitoring method for a variety of cancers. The hope is to be able to detect cancer with a high sensitivity and specificity via detection of specific exosomes in the blood or urine. The same process can also be used to more accurately monitor a patient's treatment progress. Enzyme linked lectin specific assay or ELLSA has been proven to directly detect melanoma derived exosomes from fluid samples. Previously, exosomes had been measured by total protein content in purified samples and by indirect immunomodulatory effects. ELLSA directly measures exosome particles in complex solutions, and has already been found capable of detecting exosomes from other sources, including ovarian cancer and tuberculosis-infected macrophages.
Exosomes, secreted by tumors, are also believed to be responsible for triggering programmed cell death (apoptosis) of immune cells; interrupting T-cell signaling required to mount an immune response; inhibiting the production of anti-cancer cytokines, and has implications in the spread of metastasis and allowing for angiogenesis. Studies are currently being done with "Lectin affinity plasmapheresis" (LAP), LAP is a blood filtration method which selectively targets the tumor based exosomes and removes them from the bloodstream. It is believed that decreasing the tumor-secreted exosomes in a patient's bloodstream will slow down progression of the cancer while at the same time increasing the patients own immune response.
Complementary and alternative
Complementary and alternative medicine (CAM) treatments are the diverse group of medical and health care systems, practices, and products that are not part of conventional medicine and have not been shown to be effective. "Complementary medicine" refers to methods and substances used along with conventional medicine, while "alternative medicine" refers to compounds used instead of conventional medicine. CAM use is common among people with cancer; a 2000 study found that 69% of cancer patients had used at least one CAM therapy as part of their cancer treatment. Most complementary and alternative medicines for cancer have not been rigorously studied or tested. Some alternative treatments which have been investigated and shown to be ineffective continue to be marketed and promoted.
The incidence of concurrent cancer during pregnancy has risen due to the increasing age of pregnant mothers and due to the incidental discovery of maternal tumors during prenatal ultrasound examinations.
Cancer treatment needs to be selected to do least harm to both the woman and her embryo/fetus. In some cases a therapeutic abortion may be recommended.
Radiation therapy is out of the question, and chemotherapy always poses the risk of miscarriage and congenital malformations. Little is known about the effects of medications on the child.
Even if a drug has been tested as not crossing the placenta to reach the child, some cancer forms can harm the placenta and make the drug pass over it anyway. Some forms of skin cancer may even metastasize to the child's body.
Diagnosis is also made more difficult, since computed tomography is infeasible because of its high radiation dose. Still, magnetic resonance imaging works normally. However, contrast media cannot be used, since they cross the placenta.
As a consequence of the difficulties to properly diagnose and treat cancer during pregnancy, the alternative methods are either to perform a Cesarean section when the child is viable in order to begin a more aggressive cancer treatment, or, if the cancer is malignant enough that the mother is unlikely to be able to wait that long, to perform an abortion in order to treat the cancer.
Fetal tumors are sometimes diagnosed while still in utero. Teratoma is the most common type of fetal tumor, and usually is benign. In some cases these are surgically treated while the fetus is still in the uterus.
Cancer is a significant issue that is affecting the world. Specifically in the U.S, it is expected for there to be 1,735,350 new cases of cancer, and 609,640 deaths by the end of 2018. Adequate treatment can prevent many cancer deaths but there are racial and social disparities in treatments which has a significant factor in high death rates. Minorities are more likely to suffer from inadequate treatment while white patients are more likely to receive efficient treatments in a timely manner. Having satisfactory treatment in timely manner can increase the patients likelihood of survival. It has been shown that chances of survival are significantly greater for white patients than for African American patients.
The annual average mortality of patients with colorectal cancer between 1992 and 2000 was 27 and 18.5 per 100,000 white patients and 35.4 and 25.3 per 100,000 black patients. In a journal that analyzed multiple studies testing racial disparities when treating colorectal cancer found contradicting findings. The Veterans administration and an adjuvant trial found that there were no evidence to support racial differences in treating colorectal cancer. However, two studies suggested that African American patients received less satisfactory and poor quality treatment compared to white patients. One of these studies specifically was provided by the Center for Intramural Research. They found that black patients were 41% less likely to receive colorectal treatment and were more likely to be hospitalized in a teaching hospital with less certified physicians compared to white patients. Furthermore, black patients were more likely to be diagnosed with oncologic sequelae, which is a severity of the illness in result of poorly treated cancer. Lastly, for every 1,000 patients in the hospital, there were 137.4 black patient deaths and 95.6 white patient deaths.
In a breast cancer journal article analyzed the disparities of breast cancer treatments in the Appalachian Mountains. African American women were found to be 3 times more likely to die compared to Asians and two times more likely to die compared to white women. According to this study, African American women are at a survival disadvantage compared to other races. Black women are also more likely to receive less successful treatment than white women by not receiving surgery or therapy. Furthermore, The National Cancer Institute panel, identified breast cancer treatments, given to black women, as inappropriate and not adequate compared to the treatment given to white women.
From these studies, researchers have noted that there are definite disparities in the treatment of cancer, specifically who have access to the best treatment and can receive it in a timely manner. This eventually leads to disparities between who is dying from cancer and who is more likely to survive.
The cause of these disparities is generally that African Americans have less medical care coverage, insurance and access cancer centers than other races. For an example, black patients with breast cancer and colorectal cancer were shown to be more likely to have medicaid or no insurance compared to other races. The location of the health care facility also plays a role in why African Americans receive less treatment in comparison to other races. However, some studies say that African Americans don't trust doctors and don't always seek the help they need and this explains why there are less African Americans receiving treatment. Others suggest that African Americans seek even more treatment than whites and that it is simply a lack of the resources available to them. In this case, analyzing these studies will identify the treatment disparities and look to prevent them by discovering potential causes of these disparities.
- "Cancer drugs are getting better and dearer". The Economist. 4 May 2017. Retrieved 19 May 2017.
- Enger, Eldon; et al. Concepts in Biology' 2007 Ed.2007 Edition. McGraw-Hill. p. 173. ISBN 978-0-07-126042-8. Retrieved 23 November 2012.
- "What Is Cancer?". National Cancer Institute. 17 September 2007. Retrieved 17 August 2009.
- "Cancer Fact Sheet". Agency for Toxic Substances & Disease Registry. 30 August 2002. Retrieved 17 August 2009.
- Wanjek, Christopher (16 September 2006). "Exciting New Cancer Treatments Emerge Amid Persistent Myths". Retrieved 17 August 2009.
- Hayden EC (April 2009). "Cutting off cancer's supply lines". Nature. 458 (7239): 686–7. doi:10.1038/458686b. PMID 19360048.
- Subotic, S; Wyler, S; Bachmann, A (2012). "Surgical treatment of localised renal cancer". European Urology Supplements. 11 (3): 60–65. doi:10.1016/j.eursup.2012.04.002. ISSN 1569-9056.
- Mieog JS, van der Hage JA, van de Velde CJ (October 2007). "Neoadjuvant chemotherapy for operable breast cancer". The British Journal of Surgery. 94 (10): 1189–200. doi:10.1002/bjs.5894. PMID 17701939. S2CID 34216395.
- Jafri, SH; Mills, G (2011). "Neoadjuvant BY CARSON chemotherapy in lung cancer". Therapy. 8 (1): 23–31. doi:10.2217/thy.10.82. PMC 3150241. PMID 21767368.
- "4 Best Home Remedies For Lung Cancer | HDFC Health". www.hdfchealth.com.
- Takimoto CH, Calvo E (2008). "Principles of Oncologic Pharmacotherapy". In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds.). Cancer Management: A Multidisciplinary Approach (11 ed.).
- Duarte, F J (Ed.), Tunable Laser Applications (CRC, New York, 2009) Chapters 5, 7, 8.
- Dolmans DE, Fukumura D, Jain RK (May 2003). "Photodynamic therapy for cancer". Nature Reviews. Cancer. 3 (5): 380–7. doi:10.1038/nrc1071. PMID 12724736. S2CID 205467056.
- University of Warwick (3 February 2019). "Simply shining light on dinosaur metal compound kills cancer cells". EurekAlert!. Retrieved 3 February 2019.
- Zhang, Pingyu; et al. (15 December 2018). "Nucleus‐Targeted Organoiridium–Albumin Conjugate for Photodynamic Cancer Therapy". Angewandte Chemie. 58 (8): 2350–2354. doi:10.1002/anie.201813002. PMC 6468315. PMID 30552796.
- Mo S, Carlisle R, Laga R, Myers R, Graham S, Cawood R, Ulbrich K, Seymour L, Coussios CC (July 2015). "Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours". Journal of Controlled Release. 210 (10): 10–8. doi:10.1016/j.jconrel.2015.05.265. PMID 25975831.
- Li, Ling; Hobson, Lisa; Perry, Laura; Clark, Bethany; Heavey, Susan; Haider, Aiman; Sridhar, Ashwin; Shaw, Greg; Kelly, John; Freeman, Alex; Wilson, Ian (25 June 2020). "Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer". British Journal of Cancer. 123 (6): 1024–1032. doi:10.1038/s41416-020-0951-2. ISSN 1532-1827. PMC 7493922. PMID 32581342. S2CID 220049871.
- Heavey, Susan; O'Byrne, Kenneth J.; Gately, Kathy (April 2014). "Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC". Cancer Treatment Reviews. 40 (3): 445–456. doi:10.1016/j.ctrv.2013.08.006. ISSN 1532-1967. PMID 24055012.
- Heavey, Susan; Cuffe, Sinead; Finn, Stephen; Young, Vincent; Ryan, Ronan; Nicholson, Siobhan; Leonard, Niamh; McVeigh, Niall; Barr, Martin; O'Byrne, Kenneth; Gately, Kathy (29 November 2016). "In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC". Oncotarget. 7 (48): 79526–79543. doi:10.18632/oncotarget.12755. ISSN 1949-2553. PMC 5346733. PMID 27765909.
- Luszczak, Sabina; Kumar, Christopher; Sathyadevan, Vignesh Krishna; Simpson, Benjamin S.; Gately, Kathy A.; Whitaker, Hayley C.; Heavey, Susan (2020). "PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer". Signal Transduction and Targeted Therapy. 5: 7. doi:10.1038/s41392-020-0109-y. ISSN 2059-3635. PMC 6992635. PMID 32025342.
- Ryan, Sarah-Louise; Beard, Sam; Barr, Martin P.; Umezawa, Kazou; Heavey, Susan; Godwin, Peter; Gray, Steven G.; Cormican, David; Finn, Stephen P.; Gately, Kathy A.; Davies, Anthony M. (September 2019). "Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC" (PDF). Lung Cancer (Amsterdam, Netherlands). 135: 217–227. doi:10.1016/j.lungcan.2019.07.006. ISSN 1872-8332. PMID 31446998.
- Heavey, Susan; Godwin, Peter; Baird, Anne-Marie; Barr, Martin P.; Umezawa, Kazuo; Cuffe, Sinéad; Finn, Stephen P.; O'Byrne, Kenneth J.; Gately, Kathy (October 2014). "Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC". Cancer Biology & Therapy. 15 (10): 1367–1377. doi:10.4161/cbt.29841. ISSN 1555-8576. PMC 4130730. PMID 25025901.
- Godwin, P.; Baird, A. M.; Heavey, S.; Barr, M. P.; O'Byrne, K. J.; Gately, K. (2013). "Targeting nuclear factor-kappa B to overcome resistance to chemotherapy". Frontiers in Oncology. 3: 120. doi:10.3389/fonc.2013.00120. ISSN 2234-943X. PMC 3655421. PMID 23720710.
- Damodar, S; Terunuma H; Abraham S (October 2006). "Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid Leukemia (AML) - Our Experience". Journal of Stem Cells and Regenerative Medicine. 1 (1): 40–41.
- Sivaraman, G; Pandian A; Abraham S (October 2008). "Autologous Immune Enhancement therapy for Advanced Carcinoma of Pancreas-A Case Report". Journal of Stem Cells and Regenerative Medicine. 4 (1): 1.
- Buchbinder EI, Desai A (February 2016). "CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition". American Journal of Clinical Oncology. 39 (1): 98–106. doi:10.1097/COC.0000000000000239. PMC 4892769. PMID 26558876.
- Ledford H, Else H, Warren M (October 2018). "Cancer immunologists scoop medicine Nobel prize". Nature. 562 (7725): 20–21. Bibcode:2018Natur.562...20L. doi:10.1038/d41586-018-06751-0. PMID 30279600.
- Kleinman HK, Liau G (July 2001). "Gene therapy for antiangiogenesis". Journal of the National Cancer Institute. 93 (13): 965–7. doi:10.1093/jnci/93.13.965. PMID 11438554.
- Kennedy RD, D'Andrea AD (August 2006). "DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes". Journal of Clinical Oncology. 24 (23): 3799–808. doi:10.1200/JCO.2005.05.4171. PMID 16896009.
- Shaheen M, Allen C, Nickoloff JA, Hromas R (June 2011). "Synthetic lethality: exploiting the addiction of cancer to DNA repair". Blood. 117 (23): 6074–82. doi:10.1182/blood-2011-01-313734. PMID 21441464.
- Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (July 2014). "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial". The Lancet. Oncology. 15 (8): 852–61. doi:10.1016/S1470-2045(14)70228-1. PMID 24882434.
- Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK (August 2016). "Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies". Nature Communications. 7: 12425. Bibcode:2016NatCo...712425D. doi:10.1038/ncomms12425. PMC 4979061. PMID 27498558.
- Yao, Stephanie (19 December 2014). "FDA approves Lynparza to treat advanced ovarian cancer: First LDT companion diagnostic test also approved to identify appropriate patients". U.S. Food and Drug Administration.
- Commissioner, Office of the (18 March 2019). "Press Announcements - FDA grants accelerated approval to new treatment for advanced ovarian cancer". www.fda.gov.
- Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M (June 2006). "Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer". Proceedings of the National Academy of Sciences of the United States of America. 103 (23): 8822–7. Bibcode:2006PNAS..103.8822A. doi:10.1073/pnas.0600645103. PMC 1466544. PMID 16723399.
- "American Cancer Society | Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin". www.cancer.org. Retrieved 19 April 2017.
- "WHO's pain ladder". Cancer. World Health Organization.
- Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B (December 2005). "Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group". BMJ. 331 (7528): 1295. doi:10.1136/bmj.38628.561123.7C. PMC 1298846. PMID 16299015.
- Taylor DD, Gercel-Taylor C (July 2008). "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer". Gynecologic Oncology. 110 (1): 13–21. doi:10.1016/j.ygyno.2008.04.033. PMID 18589210. as PDF
- Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH (January 2009). "Exosomal microRNA: a diagnostic marker for lung cancer". Clinical Lung Cancer. 10 (1): 42–6. doi:10.3816/CLC.2009.n.006. PMID 19289371.
- "Aethlon Medical Announces Data Against Metastatic Melanoma - Sep 9, 2010". Aethlonmedical.investorroom.com. 9 September 2010. Retrieved 21 June 2013.
- Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH (July 2008). "Exosomes as a tumor immune escape mechanism: possible therapeutic implications". Journal of Translational Medicine. 6: 37. doi:10.1186/1479-5876-6-37. PMC 2504474. PMID 18644158.DOI: 10.1038/s41392-020-0205-z
- Cassileth BR, Deng G (2004). "Complementary and alternative therapies for cancer". The Oncologist. 9 (1): 80–9. doi:10.1634/theoncologist.9-1-80. PMID 14755017.
- What Is CAM? National Center for Complementary and Integrative Health. retrieved 3 February 2008.
- Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (July 2000). "Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology". Journal of Clinical Oncology. 18 (13): 2505–14. doi:10.1200/JCO.2000.18.13.2505. PMID 10893280.
- Vickers A (2004). "Alternative cancer cures: "unproven" or "disproven"?". Ca. 54 (2): 110–8. CiteSeerX 10.1.1.521.2180. doi:10.3322/canjclin.54.2.110. PMID 15061600. S2CID 35124492.
- "Krebstherapie in der Schwangerschaft extrem schwierig" (in German). Curado. Associated Press. 20 February 2009. Retrieved 6 June 2009.
- Shugarman, Lisa R.; Mack, Katherine; Sorbero, Melony E. S.; Tian, Haijun; Jain, Arvind K.; Ashwood, J. Scott; Asch, Steven M. (2009). "Race and Sex Differences in the Receipt of Timely and Appropriate Lung Cancer Treatment". Medical Care. 47 (7): 774–781. doi:10.1097/MLR.0b013e3181a393fe. JSTOR 40221952. PMID 19536007. S2CID 12148999.
- Bigby, Judy Ann; Holmes, Michelle D. (2005). "Disparities across the Breast Cancer Continuum". Cancer Causes & Control. 16 (1): 35–44. doi:10.1007/s10552-004-1263-1. JSTOR 20069438. PMID 15750856. S2CID 28887189.
- BALL, JUDY K.; ELIXHAUSER, ANNE (September 1996). "Treatment Differences Between Blacks and Whites with Colorectal Cancer". Medical Care. 34 (9): 970–984. doi:10.1097/00005650-199609000-00008. ISSN 0025-7079. PMID 8792784.
- Couto, Richard A. (2012). Ludke, Robert L.; Obermiller, Phillip J. (eds.). Appalachian Health and Well-Being. University Press of Kentucky. ISBN 9780813135861. JSTOR j.ctt2jcssn.
- Holmes, Laurens; Opara, Franklin; Hossain, Jobayer (2010). "A Five-Year Breast Cancer-Specific Survival Disadvantage of African American Women". African Journal of Reproductive Health / La Revue Africaine de la Santé Reproductive. 14 (3): 195–200. JSTOR 41329740. PMID 21495613.
- Diehr, Paula; Yergan, John; Chu, Joseph; Feigl, Polly; Glaefke, Gwen; Moe, Roger; Bergner, Marilyn; Rodenbaugh, Jeff (1989). "Treatment Modality and Quality Differences for Black and White Breast-Cancer Patients Treated in Community Hospitals". Medical Care. 27 (10): 942–958. doi:10.1097/00005650-198910000-00005. JSTOR 3765483. PMID 2796413. S2CID 41540074.
- Palmer, Richard C.; Schneider, Eric C. (2005). "Social Disparities across the Continuum of Colorectal Cancer: A Systematic Review". Cancer Causes & Control. 16 (1): 55–61. doi:10.1007/s10552-004-1253-3. JSTOR 20069440. PMID 15750858. S2CID 9426166.
- SCHNITTKER, JASON; PESCOSOLIDO, BERNICE A.; CROGHAN, THOMAS W. (2005). "Are African Americans Really Less Willing to Use Health Care?". Social Problems. 52 (2): 255–271. doi:10.1525/sp.2005.52.2.255. JSTOR 10.1525/sp.2005.52.2.255.
- "Radiation Therapy for Brain Cancer | CTCA." CancerCenter.com. N.p., 01 Jan. 0001. Web. 21 Mar. 2017.
- "How Does Radiation Therapy Work?" American Cancer Society. N.p., n.d. Web. 21 Mar. 2017.
- "Radiation Therapy for Cancer." National Cancer Institute. N.p., n.d. Web. 21 Mar. 2017.